StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) company profile

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

About Ovid Therapeutics

Pharmaceutical Preparations, SIC 2834

Ovid is a biopharmaceutical company that develops small molecule medicines to treat central nervous system disorders. The company focuses on addressing conditions characterized by neuronal hyperexcitability, including rare epilepsies and psychiatric disorders. Its primary clinical-stage programs include OV329, a GABA-aminotransferase inhibitor evaluated for focal onset seizures, tuberous sclerosis complex, and infantile spasms, alongside a library of potassium-chloride cotransporter 2 direct activators, led by the oral candidate OV4071. Its targeted patient populations comprise individuals suffering from drug-resistant seizures, schizophrenia, and psychoses associated with Parkinson's disease and Lewy body dementia.

The company operates with a team of 23 professionals, including three medical doctors and eight scientists holding doctorate degrees. Its research and development assets include a collection of more than 100 direct activator molecules and multiple clinical development initiatives. The provided text indicates regulatory and clinical trial activities in Australia and the United States, but it does not disclose the location of the company's headquarters.

Summary of the business section of Ovid Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Ovid Therapeutics Inc.
Founded
2014
Headquarters
New York, NY
Address
441 Ninth Avenue, 14th Floor 10001
Phone
(212) 776-4381
Website
ovidrx.com
Employees
23, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, New York, New York

Stock & identifiers

Ticker
OVID
Exchange
Nasdaq
IPO date
May 5, 2017
Shares outstanding
195M, Aug 11, 2026
Public float
$22.20M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1636651
CUSIP
690469101
ISIN
US6904691010
FIGI
BBG009F0TD76
Share class FIGI
BBG009F0TD85
LEI
549300H36NUI4L6U8F17
EIN
46-5270895

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeremy M. LevinExecutive Chairman, Director3,770,509
Margaret A. AlexanderPresident and CEO, Director61,750
Charles Ross CarterChief Financial Officer44,375
Jeffrey A. RonaCBFO156,313
Anna GrekaDirector–
Bart FriedmanDirector8,789
Stelios PapadopoulosDirector217,578
Kevin Joseph FitzgeraldDirector17,578
Karen BernsteinDirector20,000
Barbara Gayle DuncanDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.93M$3.73M$995.72K$88–
FY2024$2.77M$35.98K$1.59M$29–
FY2023$2.14M$2.98M$1.08M$100–
FY2022$3.13M$1.42M$1.42M$58–
FY2021$847.07K$1.69M$802.71K$139–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jeremy M. Levin
Executive Chairman and Former Chief Executive Officer (5)
$644.05K–$744.65K$532.00K$14.00K$1.93M-30%
Margaret Alexander
President and Chief Executive Officer and Former Chief Operating Officer (5)
$515.00K$24.81K$118.47K$350.00K$14.00K$1.02M-38%
Jeffrey Rona
Chief Business & Financial Officer
$506.89K$24.81K$118.47K$305.00K$14.00K$969.16K-36%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 5, 2017
Offer price
$15.00
Securities offered
5,000,000
Gross proceeds
$75.00M
Exchange
Nasdaq
First trading day
May 5, 2017
First-day close
$12.25-18.3%
Lock-up ends (est.)
Nov 1, 2017

“The initial public offering price is $15.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 23 full-time employees, the majority of whom were primarily engaged in research and development activities, including three individuals with MD degrees and eight professionals with PhD degrees specializing in the sciences.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?